Patient‐based cost‐effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4‐year prospective randomised phase II study-Reference-Cited by-同舟云学术

Patient‐based cost‐effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4‐year prospective randomised phase II study

Published:2019-12-11 Issue:1 Volume:29 Page:
ISSN:0961-5423
Container-title:European Journal of Cancer Care
language:en
Short-container-title:Eur J Cancer Care

Author:

Wen Feng¹²,Zheng Hanrui²³,Zhang Pengfei²³,Zhou Jing²³,Chen Hongdou²³,Zhou Kexun²³,Li Qiu¹²^ORCID,Bi Feng¹

Affiliation:

1. Department of Medical Oncology West China Hospital Sichuan University Sichuan China

2. West China Biostatistics and Cost‐Benefit Analysis Center Sichuan University Sichuan China

3. Department of Clinical Pharmacy West China Hospital Sichuan University Sichuan China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ecc.13196

Reference29 articles.

1. Clinical and Economic Evaluation of First-line Therapy with FOLFIRI or Modified FOLFOX6 for Metastatic Colorectal Cancer

2. Preliminary results of a randomized phase II study: Treatment of Chinese patients with advanced gastric cancer with FOLFIRI followed by FOLFOX7 or the reverse sequence.

3. Cancer statistics in China, 2015

4. Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China

5. Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Promising first‐line immuno‐combination therapies for unresectable hepatocellular carcinoma: A cost‐effectiveness analysis;Cancer Medicine;2024-08

2. Combined modality treatment of patients with stage IV gastric cancer with peritoneal carcinomatosis;Siberian journal of oncology;2023-02-21

3. Letter: Commentary: Cost-Effectiveness Analysis of Encephaloduroarteriosynangiosis Surgery for Symptomatic Intracranial Atherosclerotic Disease;Neurosurgery;2022-06-07

4. Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China and the United states;Liver International;2021-02-08